Navigation Links
NGM Biopharmaceuticals Secures $50 Million in Series C Financing to Advance its Portfolio of Novel Therapies for Diabetes and Obesity
Date:7/18/2013

SOUTH SAN FRANCISCO, Calif., July 18, 2013 /PRNewswire/ -- NGM Biopharmaceuticals, Inc. announced today the successful completion of a $50 million Series C financing to support advancing its portfolio of potential therapeutics for the treatment of diabetes, obesity and other cardio-metabolic diseases. 

Several new investors participated in the Series C financing, including the Topspin Fund, an investment group comprised of James Simons, Leo A. Guthart, Andy Gyenes and Steven Winick.  The financing also included participation from our existing investors, including The Column Group, Prospect Venture Partners, Rho Ventures and Tichenor Ventures.  With the Series C financing, NGM has raised over $130 million since the company's founding in 2008.

"With this $50 million round of equity financing, coupled with non-dilutive capital from our collaborations with Daiichi Sankyo, Janssen, MedImmune and JDRF, NGM is well-positioned to advance the promising pipeline of candidates generated by our drug discovery efforts," said William J. Rieflin, Chief Executive Officer of NGM.  "We remain focused on delivering the next generation of first-in-class therapeutics for the treatment of diabetes and other cardio-metabolic diseases."

About NGM Biopharmaceuticals, Inc.

Founded in 2008, NGM is a privately-held drug discovery company in South San Francisco, California committed to the identification and development of transformational biologics for diabetes, obesity and other cardio-metabolic diseases.  NGM has established collaborations with Daiichi Sankyo, Janssen Pharmaceuticals, MedImmune and JDRF.  For more information, please visit the company's website at www.ngmbio.com.


'/>"/>
SOURCE NGM Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
2. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
3. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
4. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
5. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
6. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
7. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
8. Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohns Disease
9. Biopharmaceutical Industry Veterans Join Inspiration Biopharmaceuticals Board of Directors
10. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
11. Keryx Biopharmaceuticals Announces $55 Million Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2019)... ... ... A new survey by The Senior Citizens League (TSCL) indicates that ... If that doesn’t sound like enough of a challenge, at a time when the ... $1,000 per month or more. The same survey also found that, of those ...
(Date:6/18/2019)... ... June 18, 2019 , ... An unexpected and overwhelming public outcry at ... some of its directors to change their minds about supporting SB 276 , ... to protect their patients from vaccine injuries. After hearing testimony from hundreds of parents, ...
(Date:6/16/2019)... ... 2019 , ... AVIE! MedSpa and Laser Center is proud to offer ... treatment for achieving dramatic improvements to the texture and tightness of skin on any ... skin with tiny needles, spurring vibrant new collagen growth for a wide range of ...
Breaking Medicine Technology:
(Date:6/14/2019)... ... , ... is proud to present the following recently reviewed and approved providers for May 2019. , FL TOP ... , BREAST SURGERY, Dr. Debbie Berlin , CARDIOLOGY, ... Dr. Christopher J. Pastore , Dr. Yamilet Tirado , DERMATOLOGY, ...
(Date:6/13/2019)... ... June 13, 2019 , ... ... announced that it has signed a memorandum of understanding (MOU) with MMJ International ... product MMJ-001 and MMJ-002. , MMJ BioPharma Cultivation will be supplying MMJIH with ...
(Date:6/13/2019)... ... June 13, 2019 , ... In Partnership with the Smiles for ... underinsured individuals at its Mesquite, TX office on July 13th. , Dental services provided ... and extractions . For more information, please visit the Monarch Dental website ...
(Date:6/13/2019)... , ... June 13, 2019 , ... ... is proud to present the second annual Women|Future Conference and the ... allow attendees to better position themselves and their organizations in tomorrow's marketplace. , ...
(Date:6/13/2019)... N.C. (PRWEB) , ... June 13, 2019 , ... ... trial experience, is pleased to announce that Jonathan Andrus , chief business officer ... hosted by the Duke-Margolis Center for Health Policy on July 1, 2019, ...
Breaking Medicine News(10 mins):